Time filter

Source Type

HALLE, Germany

Agency: Cordis | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-IAPP-2008 | Award Amount: 960.99K | Year: 2009

The past year has been exciting for oligonucleotide-based drug discovery and development. The Nobel Prize was awarded to Mello and Fire for discovering RNA interference. There was also big investment from the Pharmaceutical industry to Biotechnology companies-pioneers in oligonucleotide therapeutics such as Sirna, Alnylam and Isis, all US-based. High expectations were therefore raised but further progress is hampered by the issue of systemic delivery; siRNA oligonucleotides are ineffective in vivo whereas antisense DNA oligonucleotides can be effective for liver-specific targets only. Therefore, delivery systems are a matter of intense investigation with the most recent advances being cationic liposomes with PEGylation or diffusible PEGylation. However, these carriers face tolerability issues, non-specific immune stimulation or limited biodistribution. Novosom has developed a completely novel carrier system based on amphoteric liposomes. This incorporates structural features with unique charge-reversal properties which result into safety and performance advantages over the current best alternative carriers. The aim of this Consortium is to built on Novosoms carrier technology to develop novel improved amphoteric liposomes with targeted delivery modalities to cells of the immune system, and to apply them for therapeutic oligonucleotide delivery to inflammatory diseases. Knowledge transfer between partners will facilitate the design of novel carriers, identification of targets and validation using in vivo models of inflammatory disease. The Consortium stems from two very successful one-to-one collaborations and proposes here a fully integrated program of translational, interdisciplinary research. Knowledge transfer between Novosom, a European leader in oligonucleotide delivery technologies, and two Academic Institutions of international standing in inflammatory disease therapeutics provides the competitiveness needed for a European team in this US-dominated field.

Marina Biotech and Novosom Ag | Date: 2009-11-24

[ Soaps; perfumery; essential oils; preparations for body and beauty care, namely, cosmetic preparations for body care, hair care preparations; Non-medicated ointments, lotions, creams and gels, skin soap, shaving cream, shaving soap, dentifrices, all afore-mentioned including also liposomes or nano capsules or microcapsules ]. [ Lipids and lipid mixtures for the manufacture of drug and medication delivery systems of active ingredients ]. [ Pharmaceutical and veterinary preparations containing liposomes, nano capsules and microcapsules for use as drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Sanitary preparations for medical purposes; Dietetic foods for medical purposes; Baby food; Medical plasters; Materials for dressing, namely, bandages and gauze; Dental filing material for stopping teeth and dental wax for dental purposes; Pesticides, fungicides, herbicides; all afore-mentioned including also liposomes or nano capsules or microcapsules ]. Scientific and technological services [ and research works and design related thereto ] in the fields of [ pharmacy, food, cosmetics and ] biotechnology; [ industrial analysis and research services in the field of pharmacy, food, cosmetics and biotechnology; services of chemical laboratories, chemical research, chemical analyses; ] scientific research and product research and development in the field of [ pharmacy, food, cosmetics and ] biotechnology. [ Providing and licensing know-how, namely, legal services in the nature of drawing up of licensing agreements and licensing of intellectual property in the fields of pharmacy, food, cosmetics and biotechnology ].

Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-2.4.2-1 | Award Amount: 15.32M | Year: 2008

The health of the EC population has never been better. However, serious public health problems remain, which cannot be ignored including high levels of premature death due to cardiovascular diseases. Thus, new preventive, diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases are needed. The atherosclerotic changes of the vascular wall are central in the development of cardiovascular complications. The traditional view that atherosclerosis is simply a lipid storage disease has recently been challenged by evidence that inflammation plays a central role in all stages of atherosclerosis. However, molecular mechanisms linking inflammation to atherosclerosis development are not fully understood, and this has severely hampered the advance of diagnostic and therapeutic programs. AtheroRemo aims to identify novel inflammatory mechanisms in vascular remodelling by combining the exploration of human biobanks with animal models and established cellular models. This new knowledge will be used to develop new preventive, diagnostic and therapeutic strategies against atherosclerotic cardiovascular disease. AtheroRemo contains several unique strengths: 1) Outstanding expertise on immunity and inflammation. Our expertise facilitates the breakthroughs in the immuno-inflammatory targeted vascular treatments. 2) Finest European cohorts to search for molecular mechanisms behind atherosclerosis development allowing us to combine underlying genetics with lipidomic profiles in multiple cohorts in order to obtain risk factors and biomarker panel related to inflammatory remodelling. 3) Accelerated target validation with novel liposomal-targeted delivery of nucleic acid-based therapeutics in appropriate animal models. Four SME partners able to exploit the new knowledge support AtheroRemo research. Thus, we expect to translate a number of novel findings into potential clinical applications such as new diagnostic tools (biomarkers) and therapeutics.

Discover hidden collaborations